HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Hairy cell leukemia (HCL) is a rare type of chronic lymphocytic leukemia characterized by the abnormal growth of B cells, a type of white blood cell. Unlike other forms of leukemia, HCL is distinguishable by the unique appearance of the cancer cells under a microscope, which have hair-like projections on their surface. This slow-growing leukemia primarily affects older adults, with a higher prevalence in men than women. The exact cause of Hairy Cell Leukemia remains unclear, and there are no well-established risk factors associated with its development. Symptoms of HCL may include fatigue, weakness, recurrent infections, and an enlarged spleen or liver. However, some individuals with HCL may not exhibit any noticeable symptoms at the time of diagnosis. Diagnosis typically involves blood tests, bone marrow biopsy, and imaging studies to assess the extent of organ involvement. HCL is considered a chronic condition, and treatment is often initiated when symptoms become problematic or if complications arise. The standard treatment for HCL is cladribine (2-CdA) or pentostatin, which are purine analogs that target and eliminate the abnormal B cells. These therapies have shown high response rates, leading to prolonged periods of remission. In some cases, splenectomy (surgical removal of the spleen) may be recommended to alleviate symptoms and improve blood counts. While HCL is generally a manageable form of leukemia, ongoing medical monitoring is essential to track the disease's progression and manage potential complications. Despite being a chronic condition, many individuals with Hairy Cell Leukemia lead relatively normal lives with appropriate medical management and support.
